Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study.
Holdaas H, Rostaing L, Serón D, Cole E, Chapman J, Fellstrøm B, Strom EH, Jardine A, Midtvedt K, Machein U, Ulbricht B, Karpov A, O'Connell PJ; ASCERTAIN Investigators. Holdaas H, et al. Transplantation. 2011 Aug 27;92(4):410-8. doi: 10.1097/TP.0b013e318224c12d. Transplantation. 2011. PMID: 21697773 Clinical Trial.
Challenges in blood pressure measurement in patients treated with maintenance hemodialysis.
Roberts MA, Pilmore HL, Tonkin AM, Garg AX, Pascoe EM, Badve SV, Cass A, Ierino FL, Hawley CM; Beta-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study Trial Management Committee. Roberts MA, et al. Am J Kidney Dis. 2012 Sep;60(3):463-72. doi: 10.1053/j.ajkd.2012.04.026. Epub 2012 Jun 15. Am J Kidney Dis. 2012. PMID: 22704141 Review.
Cardiovascular disease in patients with chronic kidney disease.
Pilmore H, Dogra G, Roberts M, Lambers Heerspink HJ, Ninomiya T, Huxley R, Perkovic V. Pilmore H, et al. Nephrology (Carlton). 2014 Jan;19(1):3-10. doi: 10.1111/nep.12148. Nephrology (Carlton). 2014. PMID: 23927055 No abstract available.
The rationale and design of the Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study.
Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Hawley CM, Isbel NM, Krum H, Pascoe EM, Tonkin AM, Vergara LA, Perkovic V; BLOCADE Study Collaborative Group. Roberts MA, et al. Among authors: pilmore hl. Nephrology (Carlton). 2015 Mar;20(3):140-7. doi: 10.1111/nep.12362. Nephrology (Carlton). 2015. PMID: 25382452 Clinical Trial.
The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.
Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group. Roberts MA, et al. Among authors: pilmore hl. Am J Kidney Dis. 2016 Jun;67(6):902-11. doi: 10.1053/j.ajkd.2015.10.029. Epub 2015 Dec 22. Am J Kidney Dis. 2016. PMID: 26717861 Clinical Trial.
Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial.
Roberts MA, Darssan D, Badve SV, Carroll RP, Fahim MA, Haluska BA, Hawley CM, Isbel NM, Marshall MR, Pascoe EM, Pedagogos E, Pilmore HL, Snelling P, Stanton T, Tan KS, Tonkin AM, Vergara LA, Ierino FL. Roberts MA, et al. Kidney Blood Press Res. 2017;42(6):1033-1044. doi: 10.1159/000485589. Epub 2017 Dec 4. Kidney Blood Press Res. 2017. PMID: 29197871 Free article. Clinical Trial.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
103 results